An elevated level of the free deaminated sialic acid, 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN), was first discovered in human ovarian cancers (OCs), suggesting that KDN may be an oncodevelopmental antigen (Inoue S, Lin SL, Chang T, Wu SH, Yao CW, Chu TY, Troy FA II, Inoue Y. 1998. J Biol Chem. 273(42):27199-27204). To determine if this unexpected finding was unique to OC, we developed an LC-MS/MS glycomic approach to quantitatively determine the level of free and conjugated forms of KDN, Neu5Ac and Neu5Gc in head and neck cancers of the throat, and in a subpopulation of matched lymph nodes. These findings were correlated with tumor (T), nodal (N), metastatic (M) involvement and the differentiation status of the tumors. The following new findings are reported: (i) The level of free KDN in 49 throat cancers and a subpopulation of 10 regional lymph nodes accounted for 94.5 and 93.3%, respectively, of the total level of KDN (∼2 µg/g); (ii) in marked contrast, the level of free Neu5Ac in throat cancer and lymph nodes accounted for only 6.5 and 5.1% of the total level of Neu5Ac (85 µg/g); (3) The level of Neu5Gc (0.03 µg/g) in throat cancers was 0.30% of the level of Neu5Ac, two-thirds were conjugated and one-third was free. The central importance of these new findings is that the elevated level of free KDN relative to free Neu5Ac and Neu5GC in throat cancers showing no lymphatic metastasis, and which are poorly to moderately differentiated, suggests that free KDN may be useful as a biomarker for detecting some early-stage cancers at biopsy, and be of possible prognostic value in determining the potential degree of malignancy.
Introduction
Neuraminic acid is the parent compound of the family of sialic acids (Sias) or nonulsonic acids that are nine-carbon acidic amino sugars that frequently cap the non-reducing termini of glycan chains (reviewed in Troy 1992 Troy , 1995 Angata and Varki 2002; Schauer 2009; Chen and Varki 2010; Sato and Kitajima 2013; Colley et al. 2014; Schnaar et al. 2014) . The most prevalent form of Sia in nature is N-acetylneuraminic acid (Neu5Ac) while N-glycolyneuraminic acid (Neu5Gc) is less common. Neu5Gc differs from Neu5Ac by having a single oxygen atom replace one of the three protons in the C-5 position of Neu5Ac. The newest member of the Sia family is the deaminated form, 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) that lacks an acyl group on carbon atom C-5, which is replaced by a hydroxyl group (Figure 1 ). Over 50 naturally occurring derivatives of Sia have been identified that result from covalent modifications of Neu5Ac, Neu5Gc and KDN (Troy 1992 (Troy , 1995 Angata and Varki lactones, thus rendering the Sia chemically neutral (Troy 1992 (Troy , 1995 Zanetta et al. 2001; Angata and Varki 2002; Schnaar et al. 2014) . A less frequent form of sialylated glycans is those containing extended chains of di-, tri-, oligo-and polySia with degrees of polymerization (DP) extending to over 400 Sia residues when determined under nonhydrolytic conditions (Iwasaki et al. 1990; Sato et al. 2000; Nakata and Troy 2005; Drake et al. 2008; Kanato et al. 2008; Sato and Kitajima 2013) .
KDN was first discovered in the cortical alveolar polysialoglycoprotein of rainbow trout eggs (Nadano et al. 1986 ). Subsequent studies showed that KDN was expressed in glycoconjugates ranging in evolutionary diversity from bacteria to humans (Nadano et al. 1986; Knirel et al. 1989; Song et al. 1991; Kimura et al. 1994; Inoue et al. 1996; Angata and Varki 2002; Inoue and Kitajima 2006) . In mammalian species, the level of KDN expression is substantially lower than Neu5Ac, yet often exceeds that of Neu5Gc Angata, Nakata, Matsuda, Kitajima, Troy 1999) . The developmental expression of KDN was first reported in rat liver where an age-dependent change in the level of KDN expression was shown to decrease from newborn to trace levels in adult, and subsequently increased again with aging (Campanero-Rhodes et al. 1999) .
The first report of KDN in humans was the unexpected discovery of an increased level of free KDN in four ovarian cancers (OCs) relative to one "normal" tissue from an ovarian tumor, and in fetal cord but not adult red blood cells (Inoue et al. 1998) . A positive correlation between the ratio of free KDN/free Neu5Ac in ovarian adenocarcinomas and stage of malignancy was also reported. These findings led to the initial suggestion that KDN may be an oncodevelopmental antigen in OC, and therefore a potential marker for recurrent disease (Inoue et al. 1998 ). This postulate was analogous to what was recognized at the time for the elevated levels of Neu5Gc in some human cancers (Malykh et al. 2001; Samraj et al. 2014) . Subsequent studies revealed, however, that Neu5Gc in these cancers was derived from a diet rich in red meat and dairy products, both of which contain high levels of Neu5Gc, and the fact that humans are unable to synthesize Neu5Gc (Diaz et al. 2009; Samraj et al. 2014 Samraj et al. , 2015 .
The biosynthetic pathway for KDN synthesis was first elucidated in trout testis by Kitajima, Troy and colleagues who showed that KDN was synthesized de novo from mannose (Angata et al. 1994 ). The following three sequential reactions were demonstrated:
The biosynthetic enzymes required for synthesis of KDNcontaining glycoconjugates must also include the CMP-KDN synthase and KDN-transferases. The CMP-KDN synthase, which activates KDN with the high-energy phosphoryl donor CTP, was initially identified in rainbow trout testis (Terada et al. 1993; Nakata et al. 2001) , while the KDN-transferase, which catalyzes synthesis of α2,8 KDN-linkages, was first described in rainbow trout ovaries (Angata et al. 1994) .
In 1999, Angata et al. showed that the intracellular level of free KDN in mouse melanoma B16 and African green monkey kidney COS-7 cells increased when the cells were cultured in a mannoserich medium compared with cells cultured without exogenous Man Angata, Nakata, Matsuda, Kitajima, Troy 1999) . Primary cultures of mouse organs grown in the presence of Man also had similar increased intracellular levels of free KDN (Go et al. 2006) . Subsequent studies showed that the oral ingestion of mannose increased the intracellular level of free KDN in mouse organs leading to the hypothesis that the level of mannose may regulate the biosynthesis of KDN (Go et al. 2006) . Further, growth of human ovarian teratocarcinoma PA-1 cells in the presence of mannose expressed high levels of both free and conjugated forms of KDN . The stage-specific expression of phosphomannoisomerase (PMI), the enzyme responsible for interconverting Fru-6-P and mannose 6-phosphate (Man-6-P), also raised the level of free KDN in mouse testis (Davis et al. 2002) .
To test the hypothesis that the level of free KDN may be elevated in human cancers other than ovarian, we developed a highly sensitive LC-MS/MS glycomic-based method to quantitatively determine the level of free and conjugated forms of KDN, Neu5Ac and Neu5Gc in head and neck cancers of the throat, and in a subpopulation of matched regional lymph nodes. Our findings reveal that higher levels of free KDN, relative to levels of free Neu5Ac and Neu5Gc, are expressed in throat cancers and in a subset of paired regional lymph nodes. This new finding supports our hypothesis that high levels of free KDN is not a characteristic unique to OC, but rather is a property shared with throat cancer and other human cancers, as described below. In marked contrast to the elevated level of free KDN in throat cancers, >95% of Neu5Ac and ∼60% of Neu5Gc are conjugated to glycoproteins and gangliosides, providing further evidence in support of our original hypothesis that free KDN in human throat cancers may be a sensitive biomarker for early diagnosis and prognosis of more aggressive forms of malignancy (Inoue et al. 1998) .
Results

LC-MS/MS glycomic method for quantification of free and conjugated forms of KDN, Neu5Ac and Neu5Gc in human throat cancers
Quantification of free and conjugated forms of KDN, Neu5Ac and Neu5Gc in human throat cancers and a subpopulation of matched lymph nodes was carried out by LC-MS/MS in the negative electrospray ionization (ESI) mode monitoring transitions m/z for KDN, Neu5Ac and Neu5Gc, as described for free Neu5Ac and KDN by Valianpour et al. (2004) , van der Ham et al. (2007) and Chen et al. (2014) . Figure 2 shows the ESI mass spectra of the negatively singlecharged [M−H] − parent ions for KDN (m/z 266.8, Figure 2A ), Neu5Ac (m/z 307.8, Figure 2B ) and Neu5Gc (m/z 323.8, Figure 2C ). These [M−H] ions were chosen as the parent ions because of their abundance and therefore high sensitivity. The ESI mass spectra of the daughter ions for KDN at m/z 86.8 ( Figure 2A ) with m/z 266.8 as the parent ion, Neu5Ac at m/z 86.9 ( Figure 2B ) with m/z 307.8 as the parent ion and Neu5Gc at m/z 115.7 ( Figure 2C ) with m/z 323.8 as the parent ion are shown in Figure 3 . These daughter ions were selected because they were the most abundant products for all three Sias, in agreement with the previous findings of Quantitative calibration curves showing linearity and sensitivity of the LC-MS/MS method for detector response as a function of Sia concentration Figure 4 shows the LC-MS/MS quantitative calibration curves demonstrating the linearity and sensitivity of detector response as a function of the concentration of free KDN ( Figure 4A ), Neu5Ac ( Figure 4B ) and Neu5Gc ( Figure 4C ). The lower limits ofdetection was <0.01 µmol/L for all three Sias, thus demonstrating the quantitative sensitivity and power of the method. The correlation coefficient (r 2 ) for all three Sias was >0.992 and recovery for all Sia species was 93.6-102.4%. The intra-and inter-day RSD was <6%. The LC column, as described under Materials and Methods, was use to partially purify the tumor and lymph node samples to reduce the potential of signal suppression or quenching by other abundant molecules.
LC-MS/MS quantitative analyses of the level of free and conjugated forms of KDN, Neu5Ac and Neu5Gc in human throat cancers, a subpopulation of paired regional lymph nodes and in non-malignant "normal"/ adjacent tissue
As shown in Table I , LC-MS/MS was used to quantitatively determine the level of free and conjugated forms of KDN, Neu5Ac and Neu5Gc in throat cancers (n = 49) and in a subpopulation of matched regional lymph nodes (n = 10) from the patients. On the basis of these results, we conclude the following:
(i) Neu5Ac is the major species of Sia (85 µg/g) found in both throat cancer and lymph nodes (∼97%), followed by KDN (1.8 µg/g) and Neu5Gc (0.03 µg/g), which accounted for 2.2 and 0.035% of the total Sia in tumor and lymph nodes, respectively. The level of all three Sia was higher in tumors compared with lymph nodes (Table I ). (ii) Of the total amount of KDN in throat cancers and matched lymph nodes, 94.4 and 91.7%, respectively was free (1.7 μg/g vs. 1.1 μg/g). This finding is consistent with the elevated level of free KDN reported earlier for OC (Inoue et al. 1998 ) and thus shows that higher levels of free KDN relative to free Neu5Ac and Neu5G and "normal"/adjacent tissue is not a characteristic unique to OC, but rather is a property shared with throat cancer and other types of human cancers, as described below. (iii) In contrast to the high levels of free KDN relative to free Neu5Ac and Neu5Gc in throat cancers, ∼95% of the Neu5Ac was conjugated in both throat cancer and lymph nodes ( Table I ). The level of free Neu5Ac in tumors accounted for only 6.5% of the total Neu5Ac (5.5 μg/g vs. 85.2 μg/g). Similarly, the level of free Neu5Ac in lymph nodes accounted for only 5.1% of the total Sia (3.6 μg/g vs. 70.8 μg/g). (iv) The mean value for the total level of free KDN in throat cancers was ∼70% higher than in the subpopulation of matched pairs of lymph nodes (1.9 μg/g vs. 1.1 μg/g) (Table II) . Importantly, as shown in Figure 5 , an x/y scatter plot of the level of free KDN ( Figure 5A ) and total level of KDN ( Figure 5B ) in tumor and lymph node demonstrates the correlation between both free and total KDN in tumors and in the paired regional lymph nodes, a finding that was statistically significant (P < 0.01). (v) While the total concentration of Neu5Gc in throat cancers was only 0.035% of the level of Neu5Ac (30 ng/g vs. 85.2 μg/g) (Table I) , it was well above the sensitivity of our LC-MS/MS detection method as described above. Two-thirds (66.7%) of the total Neu5Gc were conjugated and one-third (33.3%) was free. Similarly, the low levels of total Neu5Gc found in lymph nodes accounted for only 0.015% of the total Neu5Ac content (15 ng/g vs. 70.8 μg/g). Again, ca. one-third was free and two-thirds were conjugated. Figure 6 shows the percent distribution of the free and conjugated forms of KDN, Neu5Ac and Neu5Gc found in the 49 throat cancers and in the subpopulation of 10 match lymph nodes from the patients. (vi) Based on the mean ± S.E. shown in Table II , the level of free and conjugated KDN and Neu5Ac was ∼2-fold higher in tumor compared with the subpopulation of matched lymph nodes. The total level of Neu5Gc, however, was ∼5-fold higher in tumor than lymph nodes (60 ng/g vs. 12 ng/g), a statistically significant finding.
Evidence that there are higher levels of free KDN in at least a subset of throat cancer tissue compared with "normal" or adjacent tissue is difficult to know with certainty because of the uncertainty about the surgical margin assessment as verifiable "normal"/adjacent tissue for comparison. Nonetheless, when we analyzed the level of free KDN in 43 samples designated as "adjacent tissue" from the surgically resected throat cancer patients, we found that in 16 of these paired samples, the level of free KDN was statistically higher than in the adjacent tissue (2.0 ± 0.3 mg/g vs. 1.1 ± 0.2 mg/g). The level of free KDN in 27 of the 43 adjacent tissue samples, however, was higher than in the cancer tissue (3.1 ± 0.4 mg/g vs. 1.3 ± mg/g). The caveat of these results, therefore, is that we did not have independent verification from the pathology laboratory showing normal cytology/histology in the adjacent tissue to confirm if the tissue samples were indeed representative of normal tissue. We also found, however, that not all throat cancers showed increased levels of free KDN, suggesting that the elevated levels of unconjugated KDN was not a property common to all throat cancers but rather a property of a subset of these tumors. Similarly, the generation of free KDN does not appear to be a property of noncancerous tissue, e.g. adult RBC's.
LC-MS/MS quantitative analysis of the level of free and conjugated forms of KDN, Neu5Ac and Neu5Gc relative to T-factor classification
The pathological T (tumor) factor relates primarily to the size of the tumor. In general, the larger the T number the greater the potential for metastasis (Spiessl et al. 1982) . For H&N cancers, the T-factor is often correlated with perineural invasion. In our study of 44 throat cancers with a known T-factor classification, 9 were classified as T1 + T2 and 35 as T3 + T4. A quantitative comparison of the levels of free, conjugated and total amounts of KDN, Neu5Ac and Neu5Gc in the different T-factor classified throat cancers is shown in Table III . Based on these findings, we conclude the following:
(i) Concomitant with an increase in the size of the primary tumor (T-factor), the total level of KDN, Neu5Ac and Neu5Gc in T3 + T4 tumors was ca. 18% lower than in tumors classified as T1 + T2 (83.3 μg/g vs. 100.7 μg/g). The total level of Neu5Ac in T3 + T4 tumors (81.5 μg/g) was slightly lower than in T1 + 2 tumors (98.4 μg/g). (ii) Based on the mean ± S.E. shown in Table III , the level of free KDN in tumors classified as T1 + T2 (2.2 μg/g) was 1.3-fold higher than those classified as T3 + T4 (1.7 μg/g). In T1 + T2 tumors, the level of free KDN accounted for 95.7% of the total KDN and in T3 + T4 tumors, 94.4%. The high level of free KDN was again in contrast with the lower levels of free Neu5Ac in T1 + T2 and T3 + T4 tumors, which was 5.23 and 6.7%, respectively. demonstrating the correlation between both free and total KDN in tumors and in a subpopulation of nine matched pairs of regional lymph nodes. This correlation was statistically significant (P < 0.01). (iii) Sixty percent of the Neu5Gc was conjugated in T1 + T2 tumors and 66.7% in T3 + T4 tumors. Interestingly, in contrast to the total level of Neu5Ac in both T1 + T2 and T3 + T4 tumors, the total level of Neu5Gc was ∼2-fold higher in the more aggressive T3 + T4 tumors (30 ng/g) than in T1 + T2 tumors (15 ng/g). While low, these Neu5Gc values are well within the sensitivity of our LS-MS/MS detection method as described above, and statistically significant.
LC-MS/MS quantification of the level of free and conjugated forms of KDN, Neu5Ac and Neu5Gc relative to lymph node (N) and metastatic (M) involvement
The pathological lymph node (N) classification relates to the extent of regional and distal lymphatic involvement. N0 tumors reflect a lack of lymphatic metastasis (M), whereas throat cancers with varying levels of lymph node metastasis, rated N1 + 2 + 3, describe tumors that vary in the extent of lymphatic metastasis (Spiessl et al. 1982) . In our study, the N-factor was known for 44 of the throat cancer patients, 33 classified as N0 and 11 as N1 + 2 + 3. There were 10 paired regional lymph nodes from patients with known N-factors, including 3 classified as N0 and 7 classified as N1 + 2 + 3. The level of free and conjugated KDN, Neu5Ac and Neu5Gc in throat cancers and lymph nodes classified as N0 and N1 + 2 + 3 are summarized in Table IV . On the basis of these results, we conclude the following:
(i) Consistent with our earlier findings of elevated levels of free KDN in OCs (Inoue et al. 1998) , the level of free KDN expressed in throat cancers classified as N0 (1.90 μg/g) and those showing varying levels of metastasis (N1 + 2 + 3; 1.43 μg/g) represented ∼93-95% of the total level of KDN (Table IVA) . This finding is again in contrast with the level of free Neu5Ac that accounted for only 6.7% (5.9 μg/g) of the total level of Neu5Ac (87.8 μg/g) in N0 nodes (metastatic negative) and 5.4% (4.1 μg/g) in N1 + 2 + 3 nodes (metastatic positive). (ii) In the subpopulation of lymph nodes from patients classified as N0, the level of total free KDN (1.6 μg/g) was nearly 2-fold higher than in nodes from patients classified with N1 + 2 + 3 metastatic nodal involvement (0.9 μg/g) (Table IVB) ; (iii) Unexpectedly, the level of free Neu5Gc in N0 lymph nodes (12 ng/g) was 4-fold higher than in nodes classified as N1 + 2 + 3 (3.0 ng/g), even though the level of total Neu5Gc was similar (19 ng/g vs. 13 ng/g) in the two different nodal classifications (Table IVB) . These findings add further support to our hypothesis that a determination of the level of free KDN and Neu5Gc in tumors and lymph nodes may be a potentially useful biomarker for detecting early-stage cancers. Table IV . LC-MS/MS quantitation of the levels of free, conjugated and total levels of KDN, Neu5Ac and Neu5Gc relative to the pathological N-factor in 33 throat cancer patients classified N0 (no lymphatic metastasis) and 11 classified as N1 + 2 + 3 (lymphatic metastasis; A) In the subpopulation of matched pairs of regional lymph nodes, three patients were classified as N0, and 7 as N1 + 2 + 3 (B). Of the 45 throat cancers that were analyzed, 18 were localized in the glottis, 18 in the supraglottic region, 2 in the subglottic region and 7 were cancers of the hypopharynx (Table V) . A quantitative comparison of the level of free and conjugated KDN, Neu5Ac and Neu5Gc in these different anatomical sites is summarized in Table V . Based on these results, we conclude the following:
(i) Cancers localized in the hypopharynx expressed the highest level of total Sia (113.7 μg/g) of which 93.7% was conjugated. The percent of conjugated Neu5Ac (∼93-97%) was similar with tumors localized in the supraglottic (85.1 μg/g), glottis (82.5 μg/g) and subglottic (55.6 μg/g) regions. In contrast, 92-95% of the KDN was free, accounting for ca. 1.35-2.32% of the total amount of Sia. Approximately 62-75% of the total amount of Neu5Gc was conjugated in the tumors with the exception of those localized in the subglottic region, where all Neu5Gc was conjugated. (ii) Tumors localized in the hypopharynx contained a level of free KDN that was ∼3.4-fold higher than cancers in the subglottic region and 1.3-and 1.5-fold higher than cancers localized in the glottis and supraglottic regions, respectively. The percent of free KDN (88-95%) and conjugated KDN (5-12%) was nearly identical for tumors localized in the four different sites. (iii) Unexpectedly, the amount of total Neu5Gc detected in tumors of the hypopharynx (80 ng/g) was ∼10-fold higher than cancers localized in the glottic (8 ng/g) or subglottic region (10 ng/g), and ca. 40% higher than tumors localized in the supraglottic region (30 ng/g). While these numerical differences are striking, the validity of this potentially interesting finding remains to be confirmed because the SD of the quantity of Neu5Gc in the hypopharynx is large and n is small.
LC-MS/MS quantification of the level of free and conjugated forms of KDN, Neu5Ac and Neu5Gc relative to the differentiation status
Tumor differentiation describes the genotype and phenotype of tumor cells compared with normal cells. Well-differentiated tumors are those that more closely resemble normal cells. Poorly differentiated tumors, in contrast, show characteristics of transformed cells including faster growth rate, polyploidy and often a higher degree of malignancy (Spiessl et al. 1982) . In our study, where the differentiation status was known, 32 of the 49 throat cancers were classified as well differentiated and 17 as poorly moderately differentiated (Table VI) . The differentiation status of the subpopulation of match regional lymph nodes in our study was known for 10 nodes, of which 4 were well differentiated and 6 were poorly moderately differentiated (Table VIB) . As shown in Table VI , the level of free KDN accounted for ∼95% of the total KDN in both well differentiated and poorly moderately differentiated tumors and ∼92% in the subpopulation of matched lymph nodes. The level of free KDN in poorly moderately differentiated tumors was slightly higher than in well differentiated tumors (1.9 μg/g vs. 1.7 μg/g) (Table VIA) . Similarly, the level of free KDN in lymph nodes from patients with poorly moderately differentiated tumors was only marginally higher than in lymph nodes from patients with well-differentiated tumors (1.2 μg/g vs. 1.0 μg/g) (Table VIB) . These levels of free KDN are again in contrast with the Neu5Ac results, in which only ca. 6% was free in both well-differentiated and poorly differentiated tumors (Table VIA) . Similarly, ∼95% of the total Neu5Ac in the subset of lymph nodes was conjugated (Table VIB) . There was no difference in the level of total Neu5Ac in poorly moderately vs. well-differentiated tumors (85.1 μg/g vs. 85.3 μg/g), respectively (Table VIA) and only ∼10% difference in the level in lymph nodes from patients with poorly to moderately differentiated tumors (67.8 μg/g vs. 75.4 μg/g), respectively. This finding is in contrast with the level of free Neu5Ac in the subpopulations of lymph nodes from patients with poorly to moderately differentiated cancers, which was ∼1.7-fold higher than in nodes from patients with well-differentiated cancers (4.3 vs. 2.6 µg/g; P < 0.05) ( Table VIB) .
The level of total Neu5Gc in poorly moderately differentiated tumors (40 ng/g) was ∼2.3-fold higher than in well-differentiated tumors (17 ng/g). In lymph nodes, however, the levels were identical (∼15 ng/g). Interesting is the reciprocal relationship between the level of free and conjugated Neu5Gc in the subpopulation of well-differentiated lymph nodes (66.7% free, 33.3%, conjugated) compared with the poorly moderately differentiated nodes, where only 20% was free and 80% conjugated (Table VIB) . These findings suggest that a higher level of free Neu5Gc in well-differentiated lymph nodes and a higher level of conjugated Neu5Gc in in the more malignant, poorly moderately differentiated lymph nodes, may be of potential diagnostic value.
Discussion
In the present study, we sought to determine if the elevated level of free KDN first reported in ovarian adenocarcinomas (Inoue et al. 1998 ) was unique to OC, or was a more generalized characteristic of other human cancers. Accordingly, we developed a highly sensitive LC-MS/ MS glycomic method to quantitatively determine the level of free and conjugated forms of KDN, Neu5Ac and Neu5Gc in head and neck cancers of the throat and in a subpopulation of matched regional lymph nodes from the patients. Our present findings confirm and extend our earlier results that were based on tumor samples from only four OC patients and one "normal" control which shows that ∼95% of the total concentration of KDN in tumors from 49 throat cancer patients and in the subset of 10 matched lymph nodes was free KDN (Table I ). This confirms that the elevated level of free KDN discovered in OC is not a characteristic unique to OC but is also a fundamental property of throat cancers. Additionally, we have correlated the results of our new findings with tumor (T) (Table III) , nodal (N) (Table IV) , metastatic (M) involvement (Table II) , and the differentiation status (Table VI) and anatomical location of the tumors within different regions of the throat (Table V) .
While not reported as part of this study, we have confirmed the presence of elevated levels of free KDN and the level of free and conjugated Neu5Ac and Neu5Gc in breast, lung, ovarian, uterine, cervical and liver cancers. The details of these studies will be reported elsewhere. This study is the first to use LC-MS/MS to quantitatively determine the level of free and conjugated KDN, Neu5Ac and Neu5Gc in H&N cancers of the throat. LC-MS/MS is a more sensitive method than the HPLC-based DMB method used in our original studies (Inoue et al. 1998 ). Here we have also reported the first evidence on the level of these Sias in a subset of matched regional lymph nodes from throat cancer patients, in the anatomical location of these tumors and the differentiation status of the cancers.
The present study has revealed several important findings not previously described, including the following:
(i) The level of free KDN in throat cancers was 2-fold higher than in OC (1.7 μg/g vs. 0.8 μg/g protein) ( Figure 7A) , while the total level of Neu5Ac in OCs was ∼3-fold higher than in throat cancers (244 μg/g vs. 85 μg/g protein ( Figure 7B ). (ii) In contrast to the undetectable levels of Neu5Gc in OC by HPLC analysis of the DMB derivative (Inoue et al. 1998 ), our more sensitive LC-MS/MS method was able to detect low levels of free and conjugated Neu5Gc (∼40 and 60% of total Neu5Gc, respectively) in both throat cancers and the subpopulation of matched lymph nodes (Figures 6 and 7C ). (iii) Neu5Ac accounted for ∼98% of the total Sia found in the throat cancers, of which <2% was free. In contrast, ∼95% of the KDN, while accounting for only ∼1% of the total Sia, was free. Neu5Gc accounted for only ∼0.06%, of the total Sia, of which ∼40% was free and ∼60% conjugated. (iv) While the level of free KDN in both tumor and the subpopulation of matched lymph nodes accounted for ∼95% of the total KDN, the quantitative mean level of free KDN in tumors was approximately one-third higher than that in lymph nodes (1.7 μg/g vs. 1.1 μg/g) ( Table I ). (v) The amount of KDN in throat cancers varied as to tumor site.
For example, the level of free KDN in tumors localized in the hypopharynx was ∼3.4-fold higher than tumors of the subglottic region (2.3 μg/g vs. 0.7 μg/g) and 1.3-and 1.5-fold higher than cancers localized in the glottis (2.3 μg/g vs. 1.8 μg/g) and supraglottic regions (2.3 μg/g vs. 1.6 μg/g), respectively. However, the percentage of free and conjugated KDN in cancers from all four regions of the throat were essentially the same. (vi) The level of free KDN in throat cancers showing no lymphatic metastasis (N0) was 1.3-fold higher than tumors showing lymphatic metastasis (N1 + 2 + 3) (1.9 μg/g vs. 1.4 μg/g; Table IV ), while the level of free KDN in poorly to moderately differentiated Table VI . LC-MS/MS quantitation of the level of free, conjugated and total levels of KDN, Neu5Ac and Neu5Gc relative to the differentiation status in 32 throat cancer patients classified as "well differentiated" and 17 classified as "poorly moderately differentiated" (A) In the subpopulation of matched pairs of regional lymph nodes from 17 throat cancer patients, four were classified as "well differentiated" and six as "poorly moderately" differentiated (B).
cancers was ∼1.1-fold higher than in well-differentiated tumors (1.88 μg/g vs. 1.65 μg/g (Table VI ).
An important question that remains unresolved in this study is why do so many human cancers have elevated levels of free KDN? One possibility may result from hypoxia, a reported feature of some highly malignant cancers (Go et al. 2007) . A potential mechanism whereby hypoxia could raise the intracellular levels of free KDN in cancer cell lines was shown by the seminal studies of Sato, Kitajima and colleagues who demonstrated that hypoxia up-regulated expression of the mRNA levels and enzymatic activities of Neu5Ac-9-phosphate synthetase (NPS), PMI and stimulated the level of Man incorporation mediated via the glucose transporter, GLUT1, in several human cancer cell lines grown in 5% CO 2 , 94%N 2 and 1% O 2 (Go et al. 2007 ). The increased NPS activity facilitated synthesis of both KDN and Neu5Ac, while the increase in PMI activity and Man incorporation led to an increase in Man-6-P, the substrate for NPS, leading only to synthesis of KDN but not Neu5Ac. Subsequent studies showed higher levels of free KDN in several tumor cell lines . It is not clear, however, if these in vitro induced hypoxic studies (Table II) may provide a molecular explanation for the elevated levels of free KDN found in different human tumors or in fetal human red blood cells that are not hypoxic. This suggests that in human cancers, many of which are well vascularized via angiogenesis and not necrotic, and in fetal cord RBC that are also well oxygenated, there may be other molecular mechanisms than hypoxia to explain the unexpected elevated level of free KDN prevalent in a number of other types of human cancers.
An important corollary of these studies is that the increased level of free KDN, but not Neu5Ac or Neu5Gc, in H&N cancers of the throat that are small, show no lymphatic metastasis and are poorly to moderately differentiated suggests that the level of free KDN may be a biomarker for detecting early-stage tumors, and for making the clinical classification to determine the extent of their malignant potential. As noted above, elevated levels of free KDN relative to free Neu5Ac and Neu5Gc and "normal" adjacent tissue, is also a property of other human cancer types, highlighting the need for further studies to determine the molecular mechanism underlying this unique finding.
Our findings show that elevated levels of free KDN are expressed in throat cancers and in a subpopulation of regional lymph nodes confirms our initial studies showing increased levels of free KDN in OC (Inoue et al. 1998 ) and therefore validates that elevated levels of free KDN is not a characteristic unique to OC. In contrast, >95% of Neu5Ac and >60% of Neu5Gc in these same throat tumors were conjugated to glycoproteins and gangliosides, providing further evidence to support our hypothesis that the high levels of free KDN in human cancers may be is a sensitive biomarker for early diagnosis and prognosis of a more aggressive form of malignancy.
In summary, the central importance of these findings are 4-fold. First, they show that a highly specific and sensitive LC-MS/MS glycomic method can be used to quantitatively determine the level of free and conjugated forms of the Sias, Neu5Ac, Neu5Gc and KDN in human cancers and in a subset of matched lymph nodes. Second, the elevated level of free KDN, first discovered in human OCs, is now established as a finding not unique to OC, but is a property of other human cancers. Third, when throat caners with accompanying lymph nodes that are classified N0, reflecting a lack of metastasis, are compared with throat cancers with varying levels of lymph node metastasis (classified N1 + 2 + 3), one sees a decrease in the total amounts of all Sias, but particularly in the level of free KDN in throat cancers (1.9-1.7 µg/g) and 1.2-1.0 µg/g in lymph nodes (Table VIA and B) . Thus, the finding of elevated levels of free KDN in throat cancers not yet showing lymphatic metastasis, and that are poorly to moderately differentiated, suggests that KDN may be a potential biomarker for detecting early-stage tumors at biopsy, and be of potential prognostic value in determining the degree of malignancy. Fourth, these findings underscore the importance of further studies to elucidate the molecular mechanism underlying why elevated levels of free KDN, in contrast to Neu5Ac and Neu5Gc, exists in human cancers, and the potential biological significance of this new finding. 
Materials and methods
Reagents
Neu5Ac, Neu5Gc and KDN were purchased from Sigma Life Sciences (St. Louis, MO) and used as control standards for identification and quantitation. Acetonitrile was obtained from SK Chemicals (Seoul, South Korea). Ammonium acetate (97% purity) was obtained from EM Science (Darmstadt, Germany). Tris (99% purity) was purchased from Amresco. Trifluoroacetic acid was obtained from Biochemika (St. Louis, MO). Water was purified using the Milli-Q UF Plus system by Millipore Corp. (Bedford, MA).
Patient samples: Ethic statement
All tumor tissue samples and the subpopulation of matched lymph nodes were obtained at surgery from patients with head and neck cancers of the throat from the Department of Otorhinolaryngology, China Medical University, under a protocol approved by the Human Subjects Review Committee, and with patient approval. All procedures were carried out in accordance with ethic committee rules (Table VII) .
Characteristics of the patients are shown in Table VIII . There were 49 men and 11 women, with a mean age of 62.2 years at the time of initial diagnosis. We analyzed a total of 49 throat cancers and a subpopulation of 10 matched regional lymph nodes from the patients. All samples were stored at −80°C until use. 
Preparation of tissue extracts
All procedures were carried out at 4°C unless stated otherwise. Tumor tissue samples (20-60 mg wet wt.) were dissected into small pieces in 0.5 mL of TBS buffer (0.01 M Tris-HCl, pH 8.0, containing 0.15 M NaCl) and homogenized in a Polytron homogenizer (IKA, Staufen, Germany). The homogenate was centrifuged at 20,000 × g for 20 min and the pellet re-homogenized in 0.5 mL TBS buffer and centrifuged again at 20,000 × g for 20 min. The pellet was designated P-1. Ethanol was added to the supernatant to a final concentration of 70% and kept on ice for 6.0 h. After centrifugation at 16,000 × g for 20 min at 4°C, the precipitate, containing any sialylated conjugates was washed three times with cold 70% ethanol. The resulting pellet was designated P-2. The P-1 and P-2 fractions containing the conjugated forms of KDN, Neu5Ac and Neu5Gc were used to quantitatively determine the concentration of these Sia glycans after mild acid hydrolysis. P-1 was hydrolyzed with 0.15 M trifluoroacetic acid (TFA) at 80°C for 1.5 h. while P-2 was hydrolyzed with 0.1 M TFA at 80°C for 2.0 h. These hydrolytic conditions were pre-determined to result in maximum release of each Sia with a minimum of loss. The amount of Sia in P-1 and P-2 was designated as the total concentration of the conjugated forms of Sia in tumor and lymph node tissues, expressed as µg/g (or ng/g) wet wt. or mg/protein, unless indicated otherwise. The combined ethanol soluble supernatant fractions were concentrated by nitrogen per-evaporation and used to determine the concentration of free KDN, Neu5Ac and Neu5Gc in the tumor and lymph mode samples by LC-MS/MS.
Experimental conditions for the quantitative determination of the concentration of KDN, Neu5Ac and Neu5Gc in throat cancers by LC-MS/MS
An Agilent 1100 LC system (Agilent Technologies, Santa Rosa, CA) consisting of a loading pump, a binary pump and a temperaturecontrolled auto-sampler was maintained at 4°C. The column-cooling compartment was maintained at 20°C, and was interfaced with the ESI ion source of a triple quadrupole 3200 QTRAP mass spectrometer (Applied Biosystems/MDS SCIEX, Foster City, CA). A ZORBAX Eclipse Plus C18 column (4.6 × 250 mm, 5 µm particle size; Agilent Technologies) was used for the chromatographic separation. An Eclipse Plus C18 guard column (4.6 × 12.5 mm, 5 µm particle size; Agilent Technologies) was placed before the analytical separation column. The mobile phase A consisted of 100% H 2 O containing 0.01% ammonium acetate, and mobile phase B consisted of 100% acetonitrile at a constant flow rate (1 mL/min). The gradient was programmed as follows: 0-0.5 min, 100% A; 0.5-1 min, gradient to 10% B; 1-3.5 min, held at 10% B; 3.5-4 min, gradient returned There were a total of 50 patients, average age was 62.2 and 49 were male.
back to 100% A. The injection volume for all samples was 20 µL. The LC column was used to partially purify the Sia-containing samples that reduced the possibility of signal suppression by other molecules. The mass spectrometer was run in negative ion MRM mode. The ion source parameters were common to all analytes in the MRM method. The ion spray voltage was operated at −4.5 KV, and the source temperature was set to 550°C. The curtain gas (N 2 ) setting was 25 psi, and the collision gas (N 2 ) setting was medium, the ion source gas 1 setting was 60 psi and ion source gas 2 setting was 60 psi. The de-clustering potential, entrance potential, collision entrance potential, collision energy and collision cell exit potential were optimized for each analyte (Table VIII) .
Statistical methods
All results are expressed as ±standard error of mean. Comparison of the levels of KDN, Neu5Ac and Neu5Gc in the different tumor sites was carried out using one-way ANOVA. Comparison of Sia levels according to the differentiation status, different pathological N-factor and different T-factors were carried out using the Student's t-test. Values were considered significant at P < 0.05. Pearson's correlation was used for analyzing the correlation between KDN, Neu5Ac and Neu5Gc concentration in nine throat cancers and in the subpopulation of nine matched lymph nodes. Significant correlations were obtained if P < 0.01. The F test was used for the comparison of the slopes of the regression lines of Sia concentrations in the nine throat cancers and the subpopulation of nine matched lymph nodes from the patient specimens.
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